CTLT

Catalent, Inc. [CTLT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CTLT Stock Summary

Top CTLT Correlated Resources

CTLT


Top 10 Correlated ETFs

CTLT


Top 10 Correlated Stocks

CTLT


In the News

08:35 27 Sep 2023 CTLT

Activist Elliott makes inroads at Catalent to build value. Here's what could happen next

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.

07:22 27 Sep 2023 CTLT

Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filing its annual form 10-K with the Securities and Exchange Commission. The company has six months from Sept.

06:35 27 Sep 2023 CTLT

Why Catalent Stock Zoomed 12% Higher This Week

The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.

03:02 27 Sep 2023 CTLT

Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.

05:04 27 Sep 2023 CTLT

Why Catalent Stock Surged Nearly 5% Higher Today

The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.

04:02 27 Sep 2023 CTLT

Catalent, Inc. (CTLT) Q4 2023 Earnings Call Transcript

Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board Alessandro Maselli - President and CEO Matti Masanovich - Senior Vice President and CFO Conference Call Participants Tejas Savant - Morgan Stanley David Windley - Jefferies Jacob Johnson - Stephens Jack Meehan - Nephron Research Sean Dodge - RBC Capital Markets John Sourbeer - UBS Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Max Smock - William Blair Rachel Vatnsdal - J.P. Morgan Tim Daley - Wells Fargo Operator Good morning, ladies and gentlemen.

03:02 27 Sep 2023 CTLT

Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

12:05 27 Sep 2023 CTLT

Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott

Catalent (CTLT) shares surged more than 5% in early trading on Tuesday after the struggling drugmaker secured a deal with activist investor Elliott Investment Management.

10:22 27 Sep 2023 CTLT

Catalent nears deal with Elliott Investment Management; will explore company sale

Catalent Inc is close to a settlement deal with activist investor Elliott Investment Management, which will include the appointment new directors and a pledge to review strategic alternatives such as a sale of the company, Reuters reported, citing sources familiar with the matter.  The media outlet noted the US-based contract drugmaker is set to add four new directors proposed by Elliott to its board, including Elliott's global head of engagement, Steven Barg, a former Goldman Sachs (NYSE:GS) banker, along with former Pfizer chief financial officer Frank D'Amelio.

09:55 27 Sep 2023 CTLT

Catalent (CTLT) Stock Gains on Elliott Deal

Catalent (NYSE: CTLT ) stock is getting a boost on Tuesday after the consumer health company reached an agreement with Elliott Investment Management. This has Catalent adding four new directors to its Board while also agreeing to conduct a strategic review.

CTLT Financial details

Company Rating
Strong Buy
Market Cap
8.17B
Income
-232M
Revenue
4.28B
Book val./share
25.61
Cash/share
1.55
Dividend
-
Dividend %
-
Employees
17.8K
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
-35.6
Forward P/E
-
PEG
2.46
P/S
1.92
P/B
1.78
P/C
29.16
P/FCF
-25.55
Quick Ratio
0.83
Current Ratio
1.78
Debt / Equity
1.05
LT Debt / Equity
0.93
-
-
EPS (TTM)
-1.28
EPS next Y
-
EPS next Q
0.64
EPS this Y
-144.91%
EPS next Y
-
EPS next 5Y
-382.81%
EPS last 5Y
NAN%
Revenue last 5Y
11.17%
Revenue Q/Q
2.99%
EPS Q/Q
-61.6%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-2.13%
Inst Own
111.16%
Inst Trans
1.07%
ROA
-2%
ROE
-5%
ROC
0.01%
Gross Margin
25%
Oper. Margin
2%
Profit Margin
-5%
Payout
-
Shs Outstand
180.27M
Shs Float
180.08M
-
-
-
-
Target Price
77
52W Range
31.45-81.72
52W High
-44.2%
52W Low
+45.81%
RSI
42
Rel Volume
0.14
Avg Volume
2.51M
Volume
342.72K
Perf Week
-4.88%
Perf Month
0.24%
Perf Quarter
-30.41%
Perf Half Y
-33.05%
-
-
-
-
Beta
1.22545
-
-
Volatility
0.98%, 1.99%
Prev Close
-0.94%
Price
45.2
Change
-0.53%

CTLT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric History 2019-06-302020-06-302021-06-302022-06-30 2023-06-30
Revenue per share
17.4620.6323.827.4323.62
Net income per share
0.951.473.482.95-1.28
Operating cash flow per share
1.722.942.582.491.44
Free cash flow per share
0.21-0.17-1.51-1.26-1.78
Cash per share
2.46.355.763.061.55
Book value per share
11.6619.3323.327.2425.61
Tangible book value per share
-10.19-3.073.454.1425.61
Share holders equity per share
11.6619.3323.327.2425.61
Interest debt per share
21.2920.9619.9524.5727.81
Market cap
7.89B11B18.16B18.88B7.85B
Enterprise value
10.5B13.06B20.51B22.64B12.42B
P/E ratio
57.4249.8231.0536.38-33.83
Price to sales ratio
3.133.554.543.911.84
POCF ratio
31.8524.9741.9543.0130.07
PFCF ratio
266.53-431.18-71.8-85.44-24.37
P/B Ratio
4.693.794.643.941.69
PTB ratio
4.693.794.643.941.69
EV to sales
4.174.225.134.692.9
Enterprise value over EBITDA
36.1732.8531.931.14157.18
EV to operating cash flow
42.429.6647.3751.5647.58
EV to free cash flow
354.83-512.15-81.06-102.43-38.56
Earnings yield
0.020.020.030.03-0.03
Free cash flow yield
00-0.01-0.01-0.04
Debt to equity
1.761.040.830.881.05
Debt to assets
0.480.390.360.40.45
Net debt to EBITDA
95.193.655.1657.84
Current ratio
2.082.572.442.721.78
Interest coverage
0.561.143.222.84-0.74
Income quality
1.820.740.850
Dividend Yield
00000
Payout ratio
00.160.040.010
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.510.430.370.390
Capex to operating cash flow
-0.88-1.06-1.58-1.5-2.23
Capex to revenue
-0.09-0.15-0.17-0.14-0.14
Capex to depreciation
-0.95-1.84-2.37-1.750
Stock based compensation to revenue
0.010.020.010.010
Graham number
15.8125.2942.7342.5227.18
ROIC
0.010.010.040.03-0.01
Return on tangible assets
0.050.050.10.08-0.02
Graham Net
-24.21-20.89-18.99-22.92-26.26
Working capital
725.1M1.4B1.72B1.84B1.17B
Tangible asset value
-1.47B-460.5M579M729M4.64B
Net current asset value
-3.11B-2.58B-2.28B-2.8B-3.47B
Invested capital
1.761.040.830.881.05
Average receivables
636.1M777.25M925.05M1.03B1.01B
Average payables
223.95M288.4M353M403M424M
Average inventory
233.15M290.5M443.4M632.5M733M
Days sales outstanding
103.8598.8692.3979.4683.4
Days payables outstanding
54.5155.553.1148.248.46
Days of inventory on hand
54.8155.9977.6680.3786.71
Receivables turnover
3.513.693.954.594.38
Payables turnover
6.76.586.877.577.53
Inventory turnover
6.666.524.74.544.21
ROE
0.080.080.150.11-0.05
Capex per share
-1.51-3.11-4.08-3.75-3.22

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q4

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
7.295.686.385.735.9
Net income per share
1.0400.45-1.25-0.48
Operating cash flow per share
0.38-0.511.19-0.351.12
Free cash flow per share
-0.92-1.340.26-1.120.41
Cash per share
2.991.922.611.391.55
Book value per share
26.6426.1127.2925.9825.61
Tangible book value per share
4.054.193.623.6925.61
Share holders equity per share
26.6426.1127.2925.9825.61
Interest debt per share
23.5223.6127.2927.0727.09
Market cap
19.31B13.02B8.1B11.89B7.85B
Enterprise value
23.07B16.96B12.52B16.49B12.42B
P/E ratio
25.68025.01-13.1-22.81
Price to sales ratio
14.7112.747.0511.477.35
POCF ratio
279.89-141.5737.86-185.8438.66
PFCF ratio
-116.34-54.04176.13-58.88104.64
P/B Ratio
4.032.771.652.531.69
PTB ratio
4.032.771.652.531.69
EV to sales
17.5716.610.915.911.63
Enterprise value over EBITDA
94.92106.6752.41-785.26-129.35
EV to operating cash flow
334.28-184.3658.53-257.6661.17
EV to free cash flow
-138.95-70.38272.28-81.64165.56
Earnings yield
0.0100.01-0.02-0.01
Free cash flow yield
-0.01-0.020.01-0.020.01
Debt to equity
0.880.90.991.031.05
Debt to assets
0.40.410.440.450.45
Net debt to EBITDA
15.4424.7518.51-218.9-47.59
Current ratio
2.722.861.911.841.78
Interest coverage
4.471.882.94-0.49-1.85
Income quality
0.37462.640.280
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.390.390.380.370
Capex to operating cash flow
-3.411.62-0.792.16-0.63
Capex to revenue
-0.18-0.15-0.15-0.13-0.12
Capex to depreciation
-2.35-1.51-1.63-1.30
Stock based compensation to revenue
0.010.020.010.010
Graham number
25.02016.6227.0816.55
ROIC
0.0100.010-0.01
Return on tangible assets
0.0300.01-0.03-0.01
Graham Net
-22.42-20.57-23.65-26.06-26.26
Working capital
1.84B1.76B1.39B1.25B1.17B
Tangible asset value
729M754M652M668M4.64B
Net current asset value
-2.8B-2.81B-3.32B-3.39B-3.47B
Invested capital
0.880.90.991.031.05
Average receivables
1.17B1.25B1.45B1.25B1.01B
Average payables
411M400M373M380.5M410.5M
Average inventory
699.5M727.5M797M792.5M754M
Days sales outstanding
72.04126.9113.5891.0482.33
Days payables outstanding
45.9344.6543.3541.3846.13
Days of inventory on hand
76.5888.799.3378.1382.55
Receivables turnover
1.250.710.790.991.09
Payables turnover
1.962.022.082.181.95
Inventory turnover
1.181.010.911.151.09
ROE
0.0400.02-0.05-0.02
Capex per share
-1.31-0.83-0.93-0.76-0.71

CTLT Frequently Asked Questions

What is Catalent, Inc. stock symbol ?

Catalent, Inc. is a US stock , located in Somerset of Nj and trading under the symbol CTLT

Is Catalent, Inc. buy or a sell ?

6 stock analysts have 6 predictions with a medium analyst target price of $84.67. The lowest prediction is $41 and the highest is $132

What is CTLT stock prediction ?

What is Catalent, Inc. stock quote today ?

Catalent, Inc. stock price is $45.2 today.

Is Catalent, Inc. stock public?

Yes, Catalent, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap